'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
- Home Page
- What's New?
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Pipeline Molecules
- Research Education
- Clinical Trials
- Resources
- Contact Us
Related Resources for this page:
- Tumor Types
- Molecular Causes of Cancer
- Biological Pathways
- Therapeutic Targets
- Clinical Trials
- Cancer Biomarkers
- Breast Cancer
- Receptor-Mediated Endocytosis
- Genome instability and mutation
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- HER2+ breast cancer
- HER2 dimerization
- Research HDIs
- Slide decks and videos
- Breast Cancer
- Ovarian Cancer
- Receptor-Mediated Endocytosis
- Cytotoxic agent
- What are ADCs?
- Stable linker
- Monoclonal antibody
- Current research in ADCs
- Targeting cancers with ADCs
- Glossary
- A brief history of ADCs
- How are ADCs designed to work?
- Research ADCs
- Multimedia Resources
- Oncogenic BRAF in cancer
- VEGF in ovarian cancer
- VEGF as a prognostic factor in ovarian cancer
- Summary
- Breast Cancer
- Future Directions
Share
HER Pathways are of critical importance in cancer
— Sliwkowski MX, "Alterations in the ErbB Signaling Network in Breast Cancer"1
Beginning with benign hyperplasia and extending through invasive metastasis, a number of studies demonstrate that [HER family] receptor activation can play a major role in all aspects of cancer development.
This section of ResearchHERPathways.com introduces the HER receptors and the methods in which they interact. Click on the links below to learn more.
- What are HER receptors?
- What are ligands and how do they relate to receptors?
- How are HER receptors activated?
- What is receptor dimerization? What are downstream signaling effects?
- What tumor types are influenced by HER pathways?
- Can HER pathways be therapeutic targets?
- Summary of HER pathways in cancer
Beginning with benign hyperplasia and extending through invasive metastasis, a number of studies demonstrate that [HER family] receptor activation can play a major role in all aspects of cancer 